At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 340 enrolled
Drug / intervention
GZR18 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Chinese Obese/Overweight Patients
In Brief
A Phase 2 clinical trial evaluating GZR18 and Placebo for Obesity and Overweight. Completed, enrolled 340 participants across 1 site.
Detailed Summary
This study is a multicenter, randomized, placebo-controlled phase II clinical study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of GZR18 injection in Chinese adult obese/overweight subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Overweight
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartJun 2023
First PostedFeb 2024
Primary CompletionJun 2024
TodayJul 2026
First PostedFeb 13, 2024
Enrollment StartJun 8, 2023
Primary CompletionJun 5, 2024
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 2.4 years ago
Interventions
GZR18drug
Titrated to dose 1, dose 2, dose 3 or dose 4
Placeboother
Administered the same volume as GZR18